Vepdegestrant Breaks New Ground in ER+ Breast Cancer – The Babak Lab
The Babak Lab shared a post on LinkedIn:
“Clinical Mondays: Vepdegestrant Breaks New Ground in ER⁺ Breast Cancer
A phase 3 trial (VERITAC-2) shows the first oral PROTAC estrogen receptor degrader, vepdegestrant, significantly prolongs progression-free survival vs. fulvestrant in ESR1-mutant, ER⁺, HER2⁻ advanced breast cancer.
Study Focus:
Compare daily oral vepdegestrant with intramuscular fulvestrant in patients progressing after CDK4/6 inhibitors.
Key Insights:
- ESR1-mutant: median PFS 5.0 vs 2.1 months (HR 0.58; p < 0.001)
- All-comers: HR 0.83 (p = 0.07)
- Safety: well tolerated, low discontinuation rates
Conclusion:
Vepdegestrant delivers strong benefit in ESR1-mutated disease, marking a milestone for PROTAC therapy in breast cancer.
Image generated using Sora by OpenAI.”
Title: Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
Journal: NEJM
Authors: Mario Campone, Michelino De Laurentiis, Komal Jhaveri, Xichun Hu, Sylvain Ladoire, Anne Patsouris, Claudio Zamagni, Jiuwei Cui, Marina Cazzaniga, Timucin Cil, Katarzyna J. Jerzak, Christian Fuentes, Tetsuhiro Yoshinami, Alvaro Rodriguez-Lescure, Ahmet Sezer, Andrea Fontana, Valentina Guarneri, Andrea Molckovsky, Marie-Ange Mouret-Reynier, Umut Demirci, Yongqiang Zhang, Olga Valota, Dongrui R Lu, Marcella Martignoni, Janaki Parameswaran, Xin Zhi, Erika P. Hamilton
More posts featuring The Babak Lab on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023